Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market repurchase of 20,100 H shares on 16 April 2026, paying a total of HKD 0.59 million at prices ranging from HKD 28.48 to HKD 30.00 per share. The volume-weighted average repurchase price stood at HKD 29.39.

Following the transaction: • Issued shares outstanding (excluding treasury shares) decreased to 135.998 million, down 0.015 % from 136.018 million on 15 April 2026. • Treasury shares rose to 220,900, representing 0.16 % of the company’s issued shares at the repurchase-mandate approval date (12 February 2026). • Total issued share capital remained unchanged at 136.219 million shares, as the repurchased stock is being held in treasury rather than cancelled.

Under the existing mandate, the company is authorised to buy back up to 13.622 million shares. Cumulative repurchases under this mandate now total 220,900 shares, equivalent to 0.16 % of the authorised limit.

In accordance with Hong Kong Listing Rules, Hanx Biopharmaceuticals is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, expiring on 16 May 2026.